Published 1 year ago

Lecanemab a Game-Changer for Alzheimer's? Not So Fast

Summary by Ground News

Full findings from the CLARITY AD trial show that treatment with the monoclonal antibody lecanemab led to modest cognitive benefit in patients with early Alzheimer's disease (AD) Yet, the modest benefit got lost in some mainstream news coverage. A Lancet editorial published December 3 hopes to temper "hype and hope" regarding lecanemab.

0 Articles

All

Left

Center

Right

Medscape

Lecanemab a Game-Changer for Alzheimer's? Not So Fast

A Lancet editorial calls for 'tempering hype and hope' over lecanemab for Alzheimer's disease, which provided modest benefit with safety concerns in the CLARITY AD trial.

1 year ago·United States

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Ground News Article Assistant

Not enough coverage to generate an Article Assistant.